ClinicalTrials.Veeva

Menu

Hemodialysis and Erythrocyte Fatty-Acid Status: a Lipidomics Study

B

Benjamin Gollasch

Status

Completed

Conditions

Erythrocytes
Hemodialysis
Fatty Acid Metabolism
Lipidomics

Treatments

Other: Blood sampling

Study type

Interventional

Funder types

Other

Identifiers

NCT03857984
E2/113/08

Details and patient eligibility

About

Hypotension with potentially serious consequences for organ perfusion is a common complication in extracorporeal procedures such as hemodialysis / hemofiltration. The exact reasons for this are still insufficiently clarified. Probably periinterventional vasorelaxant released substances play a crucial role in these procedures. These substances could be due to contact of blood cells with the Membrane in the dialyzer / hemofilter arise. In this project the hypothesis will be checked, if EETs / DHETs are released by Erythrocytes during hemodialysis and thus act as potential candidate products for the result of hypotonic phases in the Dialysis.

We will determine differences in RBC fatty acids profiling in hemodialysis patients before and after dialysis intervention. Furthermore a matched control group of healthy individuals will be profiled. RBC fatty acids profiling will be achieved by using targeted HPLC-MS mass spectrometry.

It is believed that during hemodialysis / HLM / CVVH there is an increase in EETs / DHETs in the serum and in the erythrocytes. It is believed that shear forces play an important role in the release of erythrocyte EETs / DHETs.

Full description

Differences in Erythrocyte Fatty-Acid Status Profiling in:

  • before and after hemodialysis intervention
  • in hemodialysis patients and healthy individuals Venous blood will be collected from each subject in the sitting position

Enrollment

30 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for hemodialysis patients:

  • Patients who have a history of renal failure and undergo hemodialysis / hemofiltration
  • Age over 18 years
  • Ability to consent
  • There is a written consent of the study participant

Exclusion Criteria for healthy control group:

  • chronic illness requiring any medication
  • pregnancy
  • limitations regarding functioning in the hypoxic chamber
  • inability to follow simple instructions relevant or severe abnormalities in medical history, physical examination

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Erythrocyte Fatty-Acid Status
Experimental group
Description:
Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
Treatment:
Other: Blood sampling

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems